Stocktoria
Janux Therapeutics, Inc. JANX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-06-11
Janux Therapeutics, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $10.0M | $10.6M | $8.1M | $8.6M | $3.6M | $0 |
| R&D expense | $125.9M | $68.4M | $54.9M | $53.4M | $26.2M | $3.0M |
| Operating income | -$157.7M | -$98.8M | -$73.0M | -$67.1M | -$32.9M | -$4.8M |
| Income tax | $0 | $0 | $0 | — | — | — |
| Net income | -$113.6M | -$69.0M | -$58.3M | -$63.1M | -$32.7M | -$6.8M |
| EPS (diluted) | $-1.83 | $-1.28 | $-1.32 | $-1.52 | $-1.39 | — |
| Operating cash flow | -$82.2M | -$43.8M | -$50.6M | -$42.9M | -$17.0M | -$4.4M |
| Free cash flow | -$83.3M | -$44.2M | -$52.4M | -$49.4M | -$18.5M | -$4.4M |
| Cash & equivalents | $52.3M | $430.6M | $19.2M | $51.4M | $35.6M | $7.8M |
| Total assets | $1.0B | $1.1B | $380.4M | $364.0M | $379.8M | $16.2M |
| Total liabilities | $44.7M | $38.7M | $36.1M | $43.3M | $13.5M | $9.2M |
| Shareholders' equity | $956.8M | $1.0B | $344.3M | $320.7M | $366.3M | -$14.6M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | -5.6% | +31.0% | -6.1% | +136.8% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.